Furthermore, the effects of this antagonist on the expression levels of PPARγ-regulated lipid metabolism genes and the differentiation of adipocytes were studied in order to develop novel reagents with the potential to ameliorate obesity and type 2 diabetes. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.